Does Transparency Hinder Technological Novelty? Evidence from Large Pharmaceutical Firms

Hanu Tyagi (), Manuel Hermosilla () and Rachna Shah ()
Additional contact information
Hanu Tyagi: Gies College of Business, University of Illinois Urbana–Champaign, Urbana, Illinois 61820
Manuel Hermosilla: College of Business Administration, University of Illinois at Chicago, Chicago, Illinois 60607
Rachna Shah: Carlson School of Management, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455

Manufacturing & Service Operations Management, 2025, vol. 27, issue 5, 1415-1432

Abstract: Problem definition : The drug development process has historically lacked transparency, leading to selective reporting of clinical trial results. Although clinical trial transparency aims to address this issue, increased public scrutiny may make managers more risk averse, potentially stifling novel research and development (R&D) initiatives. This raises the following question. Does transparency hinder technologically novel R&D? Methodology/results : Using data from nearly 10,000 clinical trials from 2000 to 2014, we examine how a 2005 policy to increase transparency affects drug novelty. Using a continuous difference-in-differences approach, we find that transparency prompts firms to rely more on previously used technologies (i.e., exploitative R&D) without reducing their pursuit of never-before-tested technologies (i.e., exploratory R&D). We identify negative informational spillovers as a mechanism; technology failures that are now more visible because of transparency could erode confidence in related trials, prompting firms toward familiar technologies to avoid reputational damage. Consistent with this mechanism, the impact of transparency is strongest among firms with less-diversified portfolios that are the most exposed to negative informational spillovers. Managerial implications : Our primary theoretical contribution is in demonstrating the unintended negative impact of transparency on novelty. For managers, we highlight diversification as a mitigation strategy. We urge policymakers to create incentives to support novel R&D despite transparency pressures.

Keywords: pharmaceuticals; clinical trials; new technologies; transparency; natural experiments (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://dx.doi.org/10.1287/msom.2023.0527 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:ormsom:v:27:y:2025:i:5:p:1415-1432

Access Statistics for this article

More articles in Manufacturing & Service Operations Management from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher ().